|
|
|
|
|
industry news
PHARMACEUTICAL INDUSTRY NEWS
|
 |
Bayer HealthCare
Pharmaceuticals and Bayer Schering Pharma have sued Teva
Pharmaceuticals USA, Barr Pharmaceuticals and Barr Laboratories, for
false advertising and patent infringement in connection with Teva's
generic oral contraceptive, Gianvi.
Teva's product is sold as a generic version of Bayer HealthCare's oral
contraceptive YAZ, a progesterone and estrogen combination birth
control pill. It works by preventing ovulation, thickening the mucus in
the cervix, and changing the lining of the uterus.
Bayer believes Teva is offering for sale its Gianvi product with
Physician Prescribing Information that falsely claims that Gianvi's
ethinyl estradiol is 'stabilised by betadex as a clathrate.'
Bayer said that based on testing of tablets now in the US market, it
believes that Teva's Gianvi product does not in fact contain ethinyl
estradiol stabilised by betadex as a clathrate.
Further, Bayer plans to seek a temporary restraining order and a
preliminary injunction to stop Teva from making false claims about its
Gianvi product and from infringing Bayer Schering's US Patent No
5,798,338, which covers offers to sell a drug with an ethinyl estradiol
that is stabilised by betadex as a clathrate.
Abbott and Neurocrine Announce Global Agreement to Develop and
Commercialize Elagolix for the Treatment of Endometriosis
ABBOTT PARK, Ill. and SAN DIEGO, June 16 /PRNewswire-FirstCall/ --
Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX)
today announced that they have entered into a collaboration agreement
to develop and commercialize elagolix for the treatment of
endometriosis-related pain. Elagolix is a novel, first-in-class oral
gonadotropin-releasing hormone (GnRH) antagonist, which has recently
completed a phase IIb study in endometriosis. In addition to
endometriosis, elagolix will be evaluated for the treatment of uterine
fibroids.
"Extensive preclinical and clinical experience with elagolix suggests
this drug could be an important advance for women with endometriosis
and uterine fibroids, highly prevalent conditions where there is a need
for new treatments," said John Leonard, M.D., senior vice president,
pharmaceuticals, research and development, Abbott. "This agreement
enhances Abbott's late stage pipeline, with the potential for
additional compounds in earlier stage development."
Scientific American Article Says DNA Vaccines Are Reaching Their
Potential
Inovio Pharmaceuticals Scientific Advisor and DNA Vaccines Pioneer
Co-Authors Article Highlighting That DNA-Based Vaccines and Treatments
Are Poised to Become a Success Story BLUE BELL, Pa.--(BUSINESS
WIRE)--Jun 16, 2010 - Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a
leader in the development of therapeutic and preventive vaccines
against cancers and infectious diseases, announced today that
Scientific American magazine has published in its July issue an article
entitled “DNA Drugs Come of Age.” The article details the “rebirth” of
DNA vaccines, which are recognized as safer; easier and faster to
develop and manufacture; and not requiring refrigeration - in contrast
to traditional vaccines. The article states: “A new generation of
plasmid-based vaccines is proving in human and animal trials that it
can produce the desired responses while retaining the safety and other
benefits that make DNA so appealing. The same DNA-based technology is
also now expanding to other forms of immune therapy and the direct
delivery of medicines. In their mature form, such DNA-based vaccines
and treatments are poised to become a success story by addressing
several conditions that now lack effective treatments.”
FOOD INDUSTRY NEWS
Health News
Sugar-free confections have been linked to increased levels of LDL
cholesterol and a higher risk of diabetes and heart disease, according
to Dr. Mark Urman, medical director of the Heart Center at the
Cedars-Sinai Heart Institute. While the products are important for
diabetics, they comprise just under 8% of the U.S. population, and
close to 30% of Americans regularly consume foods that are either
sugar-free, reduced-sugar or sweetened with sugar substitutes, stated
NPD analyst Harry Balzer, reported The Los Angeles Times.
Kellogg’s Next Acquisition More Likely a Snack Business “Modest in Size”
16 June 2010 - Commenting on Kellogg's acquisition strategy at an
investor conference in Paris yesterday, Chief Operating Officer John
Bryant said that his company is satisfied with its current portfolio
and is not looking to buy big companies.
Nestle to Build New Plant in Russia
15 June 2010 - An investment of CHF 60 million (1.6 billion roubles)
for the construction of a new state-of-the-art factory in Russia has
been announced today by Nestlé.Earmarked for a greenfield site
in the Vyazniki district of the Vladimir region – around 300 km east of
Moscow – the new factory will produce a wide range of culinary products
under the Maggi brand.
The new plant, which will be the 14th production site under
Nestlé Russia, will create 500 new jobs in the district.
US: BASF Expands With opening of New Nutrition Ingredients Innovation
Laboratory
June 14 – BASF plans to strengthen its support services for the food
and beverage industry and has established a new Nutrition Ingredients
Innovation Laboratory at its technical center in Tarrytown, New York.
BASF closed its existing laboratory in Ledgewood, New Jersey, on March
31, 2010.
|
|
|
 |
|
